Moderna and Merck's personalised mRNA cancer vaccine cuts melanoma recurrence

Moderna and Merck announced that their personalised mRNA melanoma vaccine significantly reduces the risk of the cancer returning. The vaccine is tailored to the individual tumour mutations of each patient. The results could pave the way for a new generation of cancer treatments customised to individual cases.